BCL2L1 and lymphoma: Various studies reported a higher expression of Bcl‐xL in solid tumors, a subset of leukemia, and lymphomas than other antiapoptotic members.[5] Also, some studies found a strong correlation between the overexpression of Bcl‐xL protein with acquiring resistance to other anticancer drugs.[6] Therefore, Bcl‐xL is one of the most promising cancer targets.